Brief: BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
20/03/2024 20:24
March 21 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO ANNOUNCES INITIATION OF PHASE 2A IN FIRST LINE
NON-SMALL LUNG CANCER PATIENTS WITH A STK11 MUTATION
Source text for Eikon: ID:nPn4dGYvLa
Further company coverage: BGBIO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee